Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis

Archives of Dermatology

Volumn 145, Issue 2, 2009, Pages 157-162

  Gueudry, Julie ^a   Roujeau, Jean Claude ^b   Binaghi, Michel ^b   Soubrane, Gisèle ^b   Muraine, Marc ^a  

^a HÔPITAL CHARLES NICOLLE   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONJUNCTIVA DISEASE; CORNEA EROSION; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; DRY EYE; EYE DISEASE; FEMALE; HOSPITAL DISCHARGE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SCORING SYSTEM; STEVENS JOHNSON SYNDROME; SYMBLEPHARON; TOXIC EPIDERMAL NECROLYSIS; TOXOPLASMOSIS; TRICHIASIS; UNIVERSITY HOSPITAL; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COHORT STUDIES; EPIDERMAL NECROLYSIS, TOXIC; EYE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60349112335     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.540     Document Type: Article

References (37)

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.
2. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiformemajus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol. 1996;49(7):769-773.
3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-1285.
4. Sotozono C, Ang LP, Koizumi N, et al. New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmology. 2007;114(7):1294-1302.
5. Koizumi N, Inatomi T, Suzuki T, Sotozono C, Kinoshita S. Cultivated corneal epithelial transplantation for ocular surface reconstruction in acute phase of Stevens-Johnson syndrome. Arch Ophthalmol. 2001;119(2):298-300.
6. Nordlund ML, Holland EJ, Kersten RC. Ocular surface reconstruction in a patient with complete ankyloblepharon resulting from Stevens-johnson syndrome. Arch Ophthalmol. 2004;122(6):934-935.
7. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153.
8. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102(11):1669-1676.
9. Binaghi M, Koso M, Roujeau JC, Coscas G. Ocular complications of Lyell's syndrome: recent concepts apropos of 26 cases [in French]. J Fr Ophtalmol. 1985;8(3):239-243.
10. Arstikaitis MJ. Ocular aftermath of Stevens-Johnson syndrome. Arch Ophthalmol. 1973;90(5):376-379.
11. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118(5):615-621.
12. Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics. 2002;109(1):74-78.
13. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology. 2003;207(1):33-36.
14. Haber J, Hopman W, Gomez M, Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil. 2005;26(1):33-41.
15. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62(5):527-531.
16. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res. 2006;27(1):26-33.
17. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye. 2005;19(8):846-853.
18. Giasson CJ, Bouchard C, Boisjoly H, Germain L. Amnion and ocular surface problems [in French]. Med Sci (Paris). 2006;22(6-7):639-644.
19. Muraine M, Gueudry J, Toubeau D, et al. Advantages of amniotic membrane transplantation in eye surface diseases [in French]. J Fr Ophtalmol. 2006;29(9):1070-1083.
20. Muraine M, Descargues G, Franck O, et al. Amniotic membrane graft in ocular surface disease: prospective study with 31 cases [in French]. J Fr Ophtalmol. 2001;24(8):798-812.
21. Kobayashi A, Yoshita T, Sugiyama K, et al. Amniotic membrane transplantation in acute phase of toxic epidermal necrolysis with severe corneal involvement. Ophthalmology. 2006;113(1):126-132.
22. John T, Foulks GN, John ME, Cheng K, Hu D. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology. 2002;109(2):351-360.
23. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112(5):904-912.
24. Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002;53(3):263-280.
25. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5(5):459-463.
26. Isawi H, Dhaliwal DK. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg. 2007;33(9):1644-1646.
27. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160-1165.
28. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26(2):123-129.
29. Correia O, Chosidow O, Saiag P, Bastuji-Garin S, Revuz J, Roujeau JC. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology. 1993;186(1):32-37.
30. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns. 1996;22(4):275-278.
31. Pushker N, Tandon R, Vajpayee RB. Stevens-Johnson syndrome in India: risk factors, ocular manifestations and management. Ophthalmologica. 2000;214 (4):285-288.
32. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102(6):28S-30S.
33. Roujeau JC, Phlippoteau C, Koso M, et al. Sjogren-like syndrome after drug-induced toxic epidermal necrolysis. Lancet. 1985;1(8429):609-611.
34. Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol. 2000;130(1):25-32.
35. Vitale S, Goodman LA, Reed GF, Smith JA. Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eye. Health Qual Life Outcomes. 2004;2:44.
36. Russo PA, Bouchard CS, Galasso JM. Extended-wear silicone hydrogel soft contact lenses in the management of moderate to severe dry eye signs and symptoms secondary to graft-versus-host disease. Eye Contact Lens. 2007;33(3):144-147.
37. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007;91(8):1048-1053.